MPM Oncology Impact Management »

Immatics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Immatics (IMTX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Immatics

Tip: Access up to 7 years of quarterly data

All positions including Immatics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immatics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $4.9M 418k 11.62

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Immatics

Perceptive Advisors
T. Rowe Price Investment Management
Baker Bros. Advisors
Paradigm Biocapital Advisors
Vestal Point Capital
T. Rowe Price Associates
Woodline Partners
Citadel Advisors
OrbiMed Advisors
Goldman Sachs Group
RA Capital Management
Braidwell
Frazier Life Sciences Management
Suvretta Capital Management
Daniel D. Thurber

View all funds holding Immatics